摘要
目的探讨浸润性乳腺癌组织中组蛋白去乙酰化酶1(HDAC1)蛋白质水平和分子水平mRNA的表达意义及其与临床病理特征之间存在的相关性。方法分别应用EnVision两步法免疫组化和RT-PCR方法检测乳腺浸润性导管癌和乳腺良性增生HDAC1蛋白和HDAC1 mRNA的表达,并分析其与临床病理特征的关系,同时与Her-2蛋白表达结果比较分析。结果 (1)乳腺浸润性导管癌中,HDAC1蛋白高表达率为35.83%(43/120),对照组20例乳腺增生病变中HDAC1低表达或不表达,两者之间差异有显著性;(2)HDAC1 mRNA阳性率为63.33%(38/60),高于免疫组化法;(3)乳腺癌中HDAC1表达与Her-2(55.26%)的表达有相关性(P<0.05)。结论 (1)HDAC1蛋白在乳腺癌和乳腺良性增生性病变中有差异,HDAC1在浸润性乳腺癌的发生、发展中起重要作用,对判断预后有积极意义;(2)RT-PCR方法检测结果更可靠、更敏感;(3)HDAC1抑制剂有望成为乳腺癌患者治疗的新靶向药物。
Purpose To study the expression of histone deacetylase 1（HDAC1） protein and mRNA in invasive breast cancer and the correlation with clinicopathologic features.Methods HDAC1 protein and mRNA expression were delectded by immunohistochemistry and RT-PCR method in breast cancer and benign breast,and studied the relationship with clinicopathological features and Her-2 protein expression.Results（1） HDAC1 protein expression rate was 35.83%（43/120） in breast cancer,there is low expression or no expression in 20 cases of breast hyperplasia,and the significant differences between them.（2）HDAC1 mRNA positive rate was 63.33%（38/60） which it was higher than immunohistochemistry.（3）The correlation was found between HDAC1 and Her-2（55.26%） in breast cancer（P0.05）.Conclusions（1）There was difference between breast cancer and breast benign proliferative lesions in HDAC1 protein expression.HDAC1 may play an important role in the development of invasive breast cancer and it is a valuable prognostic marker.（2）The results tested by RT-PCR are more sensitive than immunohistochemistry.（3）HDAC1 inhibitors was expected to become a new targeted therapy drugs for breast cancer patients.
出处
《临床与实验病理学杂志》
CAS
CSCD
北大核心
2011年第9期929-932,共4页
Chinese Journal of Clinical and Experimental Pathology
基金
南通市科技局社会发展计划(S2007012)
